FDA clears phase II trial of IkT-001 for JC virus infection
Posted: Wed Aug 17, 2011 1:03 am
Inhibikase Therapeutics, Inc., an emerging leader in infectious disease, announced today that it has received FDA clearance to commence a Phase II proof-of-concept trial for its lead compound IkT-001. IkT-001, a host-directed kinase inhibitor, is intended to clear JC polyomavirus (JCV) infection, the causative agent of Progressive Multifocal Leukoencephalopathy (PML).
This proof-of-concept trial will be conducted in multiple sclerosis (MS) patients on natalizumab (Tysabri®), a patient group that is at significant risk for developing the potentially fatal PML disease. JCV progresses to PML only in patients with chronic or drug-induced immune suppression, to include patients diagnosed with clinical AIDS or who are receiving monoclonal antibody treatment for MS, lupus, rheumatoid arthritis, leukemia or lymphoma.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1768